Silexion Therapeutics completes preclinical studies of SIL204 in KRAS-driven colorectal, lung, and pancreatic cancers

Silexion Therapeutics Corp

SIL204 evaluated in GP2D (colorectal), A427 (lung), and Panc-1 (pancreatic) KRAS-mutant cell lines.
Company expects to announce comprehensive results within the next few days.
If positive, SIL204 could expand development strategy beyond pancreatic cancer.
Global treatment markets for these three KRAS-driven cancers estimated at over $30 billion annually.
KRAS mutations drive ~90% of pancreatic, ~45% of colorectal, and ~35% of non-squamous NSCLC.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.